OP
LCTX icon

ORG Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

ORG Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$57.8K Sell
34,600
-1,100
-3% -$1.9K 0.01% 559
2025
Q3 		$60.3K Sell
35,700
-23,500
-40% -$27.8K 0.01% 550
2025
Q2 		$53.1K Sell
59,200
-56,200
-49% -$33.3K 0.01% 526
2025
Q1 		$47.4K Buy
+115,400
New +$67.7K 0.01% 496

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ORG Partners's LCTX Position: Q4 2025 in Review

ORG Partners reduced its Lineage Cell Therapeutics (LCTX) stake by 3.1% in Q4 2025, selling an estimated $1.9K and leaving 34,600 shares worth $57.8K. The position accounts for 0.01% of the portfolio, ranked #559.

ORG Partners first reported a position in LCTX in Q1 2025 and has held it in 4 quarters since. The position peaked at $60.3K in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

  • ORG Partners held 34,600 shares of Lineage Cell Therapeutics worth $57.8K as of Q4 2025.
  • ORG Partners sold 1,100 Lineage Cell Therapeutics shares in Q4 2025, an estimated $1.9K.
  • Lineage Cell Therapeutics made up 0.01% of ORG Partners's portfolio in Q4 2025, its #559 holding.
  • ORG Partners first reported a position in Lineage Cell Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • ORG Partners's Lineage Cell Therapeutics position peaked at $60.3K in Q3 2025.
  • 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.